Lista de obras - Annalisa Chiappella - Dominio Público Uruguay

A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.

artículo científico publicado en 2015

A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma.

artículo científico publicado en 2014

A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients

artículo científico publicado en 2016

Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence

artículo científico publicado en 2019

Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21.

artículo científico publicado en 2009

Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi.

artículo científico publicado en 2014

Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial

artículo científico publicado en 2017

Brentuximab vedotin-based salvage treatment in Hodgkin's lymphoma

scientific article published on 16 August 2018

CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies?

artículo científico publicado en 2016

CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies.

artículo científico publicado en 2018

Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network

artículo científico publicado en 2013

Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion.

artículo científico publicado en 2011

Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the

scientific article published on 15 November 2011

Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives

artículo científico publicado en 2017

Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study

artículo científico publicado en 2017

Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome.

artículo científico publicado en 2011

Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue

article

Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study

artículo científico publicado en 2009

Epigenomic evolution in diffuse large B-cell lymphomas

artículo científico publicado en 2015

Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP

Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma

article

Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21.

artículo científico publicado en 2010

High-grade B-cell lymphoma: how to diagnose and treat

artículo científico publicado en 2019

Highlights in lymphoma: overview of the 11th International Conference on Malignant Lymphoma.

artículo científico publicado en 2011

Histological transformation and secondary malignancies in follicular lymphoma

artículo científico publicado en 2018

Impressive and durable response in a case of multiple relapsed mantle cell lymphoma treated with bortezomib and rituximab

artículo científico publicado en 2016

Integrated profiling of diffuse large B-cell lymphoma with 7q gain

artículo científico publicado en 2011

Integrating novel drugs to chemoimmunotherapy in diffuse large B-cell lymphoma.

artículo científico publicado en 2017

Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma

artículo científico publicado en 2019

Intensified therapy in diffuse large B-cell lymphoma.

artículo científico publicado en 2017

Inter- and intratumoral heterogeneity of BCL2 correlates with IgH expression and prognosis in follicular lymphoma.

artículo científico publicado en 2014

Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.

artículo científico publicado en 2012

Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy

artículo científico publicado en 2009

Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas

artículo científico publicado en 2017

Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice

artículo científico publicado en 2019

Lenalidomide in diffuse large B-cell lymphomas.

artículo científico

Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial

artículo científico publicado en 2014

Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials

article

Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi

artículo científico publicado en 2013

Monoclonal antibody-drug conjugates in B-cell lymphomas

artículo científico publicado en 2019

Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial

artículo científico publicado en 2009

Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi

artículo científico publicado en 2013

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program

artículo científico publicado en 2013

Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma

artículo científico publicado en 2016

Procalcitonin as a predictive marker of infections in chemoinduced neutropenia

artículo científico publicado en 2009

Prognostic Role of Pre-Radiation Therapy (18)F-Fluorodeoxyglucose Positron Emission Tomography for Primary Mediastinal B-Cell Lymphomas Treated with R-CHOP or R-CHOP-Like Chemotherapy Plus Radiation

artículo científico publicado en 2016

ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma

artículo científico

Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy

artículo científico publicado en 2013

Rituximab and autologous stem-cell transplantation for high-risk diffuse large B-cell lymphoma - Authors' reply

artículo científico publicado en 2017

Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study

artículo científico publicado en 2009

Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italia

artículo científico publicado en 2013

Rituximab plus Bendamustine as front line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin's lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi.

artículo científico publicado en 2018

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi

artículo científico publicado en 2016

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

artículo científico publicado en 2017

Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.

artículo científico publicado en 2008

Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.

artículo científico publicado en 2015

Salvage regimens for Hodgkin's lymphoma in the brentuximab vedotin era.

artículo científico publicado en 2017

Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi

artículo científico publicado en 2018

State-of-the-art Therapy for Advanced-stage Diffuse Large B-cell Lymphoma.

artículo científico publicado en 2016

The risk of CNS involvement in aggressive lymphomas in the rituximab era.

artículo científico publicado en 2013

Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death

artículo científico publicado en 2018

Update in indolent non-Hodgkin lymphoma (NHL): paradigm for Waldenström's macroglobulinemia (WM)

artículo científico publicado en 2011

Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network

artículo científico publicado en 2012

XVI. CNS prophylaxis in aggressive lymphomas: for whom and how.

artículo científico

Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.

artículo científico publicado en 2018

Lista de obras de Annalisa Chiappella

A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.

A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma.

A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients

Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence

Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21.

Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi.

Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial

Brentuximab vedotin-based salvage treatment in Hodgkin's lymphoma

CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies?

CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies.

Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network

Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion.

Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the

Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives

Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study

Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome.

Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue

Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study

Epigenomic evolution in diffuse large B-cell lymphomas

Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP

Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma

Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21.

High-grade B-cell lymphoma: how to diagnose and treat

Highlights in lymphoma: overview of the 11th International Conference on Malignant Lymphoma.

Histological transformation and secondary malignancies in follicular lymphoma

Impressive and durable response in a case of multiple relapsed mantle cell lymphoma treated with bortezomib and rituximab

Integrated profiling of diffuse large B-cell lymphoma with 7q gain

Integrating novel drugs to chemoimmunotherapy in diffuse large B-cell lymphoma.

Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma

Intensified therapy in diffuse large B-cell lymphoma.

Inter- and intratumoral heterogeneity of BCL2 correlates with IgH expression and prognosis in follicular lymphoma.

Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.

Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy

Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas

Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice

Lenalidomide in diffuse large B-cell lymphomas.

Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial

Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials

Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi

Monoclonal antibody-drug conjugates in B-cell lymphomas

Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial

Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program

Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma

Procalcitonin as a predictive marker of infections in chemoinduced neutropenia

Prognostic Role of Pre-Radiation Therapy (18)F-Fluorodeoxyglucose Positron Emission Tomography for Primary Mediastinal B-Cell Lymphomas Treated with R-CHOP or R-CHOP-Like Chemotherapy Plus Radiation

ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma

Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy

Rituximab and autologous stem-cell transplantation for high-risk diffuse large B-cell lymphoma - Authors' reply

Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study

Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italia

Rituximab plus Bendamustine as front line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin's lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi.

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.

Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.

Salvage regimens for Hodgkin's lymphoma in the brentuximab vedotin era.

Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi

State-of-the-art Therapy for Advanced-stage Diffuse Large B-cell Lymphoma.

The risk of CNS involvement in aggressive lymphomas in the rituximab era.

Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death

Update in indolent non-Hodgkin lymphoma (NHL): paradigm for Waldenström's macroglobulinemia (WM)

Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network

XVI. CNS prophylaxis in aggressive lymphomas: for whom and how.

Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.